Hereditary Breast Ovarian Cancer Syndrome disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HRD200 MIFTS: 58	Hereditary Breast Ovarian Cancer Syndrome Categories: Reproductive diseases, Rare diseases, Genetic diseases, Cancer diseases, Endocrine diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Hereditary Breast Ovarian Cancer Syndrome

MalaCards integrated aliases for Hereditary Breast Ovarian Cancer Syndrome:

Name: Hereditary Breast Ovarian Cancer Syndrome ¹²

Hereditary Breast and Ovarian Cancer Syndrome ⁵⁹ ²⁹ ⁶ ⁴⁴ ⁷³

Brca1- and Brca2-Associated Hereditary Breast and Ovarian Cancer ¹² ²⁴

Hereditary Breast Ovarian Cancer ¹⁵

Hboc ²⁴

Characteristics:

Orphanet epidemiological data:

⁵⁹

hereditary breast and ovarian cancer syndrome
Inheritance: Autosomal dominant; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases Cancer diseases
Anatomical: Reproductive diseases Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasm of breast

Malignant neoplasms of female genital organs

Malignant neoplasm of ovary

Orphanet: ⁵⁹

Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology ¹² DOID:5683

MeSH ⁴⁴ D061325

NCIt ⁵⁰ C8493

Orphanet ⁵⁹ ORPHA145

ICD10 via Orphanet ³⁴ C50 C56

UMLS via Orphanet ⁷⁴ C0677776

SNOMED-CT via HPO ⁶⁹ 2092003 372244006 126859007 more

UMLS ⁷³ C0677776

Sources

Summaries for Hereditary Breast Ovarian Cancer Syndrome

Disease Ontology : ¹² An autosomal dominant disease characterized by the higher than normal tendency associated with BRCA1 and BRCA2 to develop breast and ovarian cancers in genetically related families.

MalaCards based summary : Hereditary Breast Ovarian Cancer Syndrome, also known as hereditary breast and ovarian cancer syndrome, is related to endometrial cancer and ovarian cancer. An important gene associated with Hereditary Breast Ovarian Cancer Syndrome is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways/superpathways are Gene Expression and Cell Cycle, Mitotic. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and ovary, and related phenotypes are abnormality of the fallopian tube and primary peritoneal carcinoma

Wikipedia : ⁷⁶ Hereditary breast–ovarian cancer syndromes (HBOC) are cancer syndromes that produce higher than normal... more...

GeneReviews: NBK1247

Sources

Related Diseases for Hereditary Breast Ovarian Cancer Syndrome

Diseases in the Hereditary Breast Ovarian Cancer Syndrome family:

Breast-Ovarian Cancer, Familial 1	Breast-Ovarian Cancer, Familial 2
Breast-Ovarian Cancer, Familial 3	Breast-Ovarian Cancer, Familial 4

Diseases related to Hereditary Breast Ovarian Cancer Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)

#	Related Disease	Score	Top Affiliating Genes
1	endometrial cancer	28.3	BRCA1 BRCA2 MLH1 MSH2 PTEN TP53
2	ovarian cancer	26.0	ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
3	brca2 hereditary breast and ovarian cancer syndrome	11.7
4	brca1 hereditary breast and ovarian cancer syndrome	11.1
5	hereditary site-specific ovarian cancer syndrome	11.0	BRCA1 BRCA2
6	tracheoesophageal fistula with or without esophageal atresia	11.0	BRCA2 PALB2
7	breast reconstruction	10.9	BRCA1 BRCA2
8	tuberculous salpingitis	10.9	BRCA1 BRCA2
9	nosophobia	10.9	BRCA1 BRCA2
10	cancerophobia	10.9	BRCA1 BRCA2
11	breast-ovarian cancer, familial 1	10.8	BRCA1 BRCA2 NBN
12	uterine corpus serous adenocarcinoma	10.7	BRCA1 BRCA2 TP53
13	fallopian tube adenocarcinoma	10.7	BRCA1 BRCA2 TP53
14	glycogen-rich clear cell breast carcinoma	10.7	BRCA1 BRCA2 TP53
15	primary peritoneal carcinoma	10.7	BRCA1 BRCA2 TP53
16	mutagen sensitivity	10.7	BRCA1 BRCA2 TP53
17	pre-malignant neoplasm	10.7	BRCA1 BRCA2 TP53
18	fallopian tube carcinoma	10.7	BRCA1 BRCA2 TP53
19	ovarian cancer 1	10.7	BRCA1 BRCA2 TP53
20	malignant ovarian surface epithelial-stromal neoplasm	10.7	BRCA1 BRCA2 TP53
21	ovary epithelial cancer	10.7	BRCA1 BRCA2 TP53
22	li-fraumeni syndrome 2	10.7	CHEK2 TP53
23	breast carcinoma in situ	10.7	BRCA1 BRCA2 TP53
24	ductal carcinoma in situ	10.6	BRCA1 BRCA2 TP53
25	bap1 tumor predisposition syndrome	10.6	BRCA2 MRE11 PALB2
26	tumor predisposition syndrome	10.6	BRCA2 MRE11 PALB2
27	myxosarcoma	10.6	ATM BRCA1 TP53
28	tetraploidy	10.6	BRCA2 TP53
29	peutz-jeghers syndrome	10.5	BRCA2 PTEN TP53
30	congenital hypoplastic anemia	10.5	BRCA2 BRIP1 RAD51
31	nijmegen breakage syndrome-like disorder	10.4	MRE11 RAD50
32	ataxia-telangiectasia-like disorder 1	10.4	MRE11 NBN
33	renal cell carcinoma, papillary, 1	10.3	ATM PTEN TP53
34	lig4 syndrome	10.3	ATM NBN XRCC2
35	female reproductive endometrioid cancer	10.3	PTEN TP53
36	differentiated thyroid carcinoma	10.2	CHEK2 TP53 XRCC2
37	cowden disease	10.2	BRCA1 BRCA2 PTEN XRCC2
38	richter's syndrome	10.2	ATM MLH1 TP53
39	female breast cancer	10.2	ATM BRCA1 BRCA2 PALB2 TP53
40	tracheoesophageal fistula	10.2	BRCA2 BRIP1 PALB2 PTEN RAD51C
41	endometrial adenocarcinoma	10.1	MLH1 PTEN TP53
42	actinic cheilitis	10.1	MSH2 TP53
43	alpha-thalassemia/mental retardation syndrome, x-linked	10.1	MRE11 NBN RAD50 TP53
44	synchronous bilateral breast carcinoma	10.1	ATM BRCA1 BRCA2 PTEN TP53
45	bilateral breast cancer	10.0	ATM BRCA1 BRCA2 CHEK2 RAD51
46	appendix carcinoid tumor	10.0	MLH1 MSH2
47	brain cancer	10.0	BRCA2 PTEN RAD51 TP53
48	adenosquamous colon carcinoma	10.0	MLH1 MSH2
49	papillary serous adenocarcinoma	9.9
50	adenocarcinoma	9.9

Graphical network of the top 20 diseases related to Hereditary Breast Ovarian Cancer Syndrome:

Sources

Symptoms & Phenotypes for Hereditary Breast Ovarian Cancer Syndrome

Human phenotypes related to Hereditary Breast Ovarian Cancer Syndrome:

⁵⁹ ³² (show all 7)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	abnormality of the fallopian tube ⁵⁹ ³²	hallmark (90%)	Very frequent (99-80%)	HP:0011027
2	primary peritoneal carcinoma ⁵⁹ ³²	hallmark (90%)	Very frequent (99-80%)	HP:0030406
3	ovarian neoplasm ⁵⁹ ³²	hallmark (90%)	Very frequent (99-80%)	HP:0100615
4	breast carcinoma ⁵⁹ ³²	frequent (33%)	Frequent (79-30%)	HP:0003002
5	melanoma ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0002861
6	neoplasm of the pancreas ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0002894
7	prostate cancer ⁵⁹ ³²	occasional (7.5%)	Occasional (29-5%)	HP:0012125

GenomeRNAi Phenotypes related to Hereditary Breast Ovarian Cancer Syndrome according to GeneCards Suite gene sharing:

²⁶ (show all 12)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased homologous recombination repair frequency	GR00151-A-1	10.83	BRCA1 BARD1 RAD51 XRCC2
2	Decreased homologous recombination repair frequency	GR00151-A-2	10.83	BRCA1 RAD51 XRCC2
3	Decreased homologous recombination repair frequency	GR00236-A-1	10.83	BARD1 BRCA1 RAD51 BRCA2 PALB2
4	Decreased homologous recombination repair frequency	GR00236-A-2	10.83	BARD1 BRCA2 BRCA1 ATM RAD51 PALB2
5	Decreased homologous recombination repair frequency	GR00236-A-3	10.83	BARD1 BRCA2 BRCA1 RAD51 PALB2
6	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	10.42	BRCA2 BRCA1 ATM BARD1 PTEN MLH1
7	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	10.42	BRCA2 BRCA1 ATM BARD1 MLH1 PTEN
8	Increased viability with MLN4924 (a NAE inhibitor)	GR00250-A-3	10.21	BRCA2 BRCA1 ATM BARD1 MRE11 RAD50
9	Decreased viability with cisplatin	GR00101-A-4	9.72	BRCA2 BRCA1 BARD1 BRIP1 RAD51
10	Synthetic lethal with cisplatin	GR00101-A-1	9.55	BRCA2 BRCA1 BARD1 BRIP1 RAD51
11	Decreased viability after ionizing radiation	GR00232-A-2	9.54	BRCA1 ATM BRCA2
12	Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation	GR00016-A	9.1	BARD1 BRCA1 MRE11 MSH2 BRCA2 RAD51D

MGI Mouse Phenotypes related to Hereditary Breast Ovarian Cancer Syndrome:

⁴⁶ (show all 13)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.45	BRCA1 CHEK2 ATM BRCA2 BARD1 BRIP1
2	embryo	MP:0005380	10.34	BRCA1 ATM BRCA2 BARD1 RAD51 XRCC2
3	growth/size/body region	MP:0005378	10.27	BARD1 BRCA1 ATM BRCA2 TP53 RAD50
4	endocrine/exocrine gland	MP:0005379	10.22	BRIP1 BRCA1 CHEK2 ATM BRCA2 PTEN
5	homeostasis/metabolism	MP:0005376	10.22	BRIP1 CHEK2 BRCA1 ATM BRCA2 TP53
6	mortality/aging	MP:0010768	10.19	BRCA1 CHEK2 ATM BRCA2 BARD1 PTEN
7	hematopoietic system	MP:0005397	10.13	CHEK2 BRCA1 ATM BRCA2 RAD50 TP53
8	integument	MP:0010771	10.07	BRCA1 ATM BRCA2 RAD50 MSH2 PTEN
9	neoplasm	MP:0002006	10.06	BRCA1 CHEK2 ATM BRCA2 BARD1 BRIP1
10	digestive/alimentary	MP:0005381	10.05	BRCA1 BRCA2 RAD50 TP53 MSH2 PTEN
11	limbs/digits/tail	MP:0005371	9.92	BRCA1 BRCA2 TP53 RAD50 PTEN XRCC2
12	nervous system	MP:0003631	9.83	BRIP1 BRCA1 CHEK2 ATM BRCA2 BARD1
13	reproductive system	MP:0005389	9.36	BRIP1 BRCA1 ATM BRCA2 PTEN RAD51C

Sources

Drugs & Therapeutics for Hereditary Breast Ovarian Cancer Syndrome

Drugs for Hereditary Breast Ovarian Cancer Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Carboplatin

Approved

Phase 2,Phase 1

41575-94-4

10339178 498142 38904

Synonyms:

(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum

/h1-3H2,(H,7,8)(H,9,10)

1,1-Cyclobutanedicarboxylate diammine platinum (II)

1,1-Cyclobutanedicarboxylate diammine platinum(II)

2*-1

2*1H2

41575-94-4

70903-55-8

AC-1457

AC1L8I6U

Ambap41575-94-4

azanide

Blastocarb

BSPBio_003145

C 2538

C2043

C2538_SIGMA

C6H10N2O4Pt

Carbopaltin

Carboplat

carboplatin

Carboplatin

Carboplatin (JAN/USP/INN)

Carboplatin (USAN)

Carboplatin [USAN:INN:BAN:JAN]

Carboplatine

Carboplatine [French]

Carboplatino

Carboplatino [Spanish]

Carboplatinum

Carboplatinum [Latin]

Carbosin

Carbotec

Cbdca

CBDCA

CCRIS 3404

CHEBI:31355

CHEMBL1351

CHEMBL288376

CID10339178

CID2567

CID38904

CID426756

CID498142

CID5352133

CID6398587

CID6603770

cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)

cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato) platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(cyclobutanedicarboxylato)platinum II

Cyclobutane-1,1-dicarboxylate

cyclobutane-1,1-dicarboxylic acid

D01363

DB00958

Diammine(1,1-cyclobutanedicarboxylato)platinum (II)

Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum

diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum

Diammine-1,1-cyclobutane dicarboxylate platinum II

DivK1c_000892

EINECS 255-446-0

Ercar

EU-0100230

HMS1921J16

HMS2090M05

HMS2092B22

HMS502M14

HSDB 6957

I14-2390

IDI1_000892

InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6

IUPAC: Azane

JM 8

JM8

JM-8

KBio1_000892

KBio2_002009

KBio2_004577

KBio2_007145

KBio3_002645

KBioGR_000713

KBioSS_002009

Lopac0_000230

Lopac-C-2538

LS-117689

MolPort-003-665-501

MolPort-003-845-609

NCGC00015223-01

NCGC00093695-01

NCGC00094961-01

NCGC00094961-02

NCGC00094961-03

NCGC00162099-01

NCGC00162099-02

NCGC00167800-01

NCGC00178242-01

nchembio.573-comp10

nchembio773-comp2

nchembio873-comp3

Nealorin

Neocarbo

NINDS_000892

NSC 201345

NSC 241240

NSC201345

NSC241240

NSC-241240

Paraplatin

Paraplatin (TN)

Paraplatin, Carboplatin

Paraplatin-AQ

Platinum(+2) Cation

platinum(2+)

Platinum(II), (1, 1-cyclobutanedicar

Platinum, {diammine[1,1-cyclobut

Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)

Ribocarbo

S1215_Selleck

SPBio_000716

Spectrum_001529

SPECTRUM1502106

Spectrum2_000898

Spectrum3_001503

Spectrum4_000337

Spectrum5_001094

UNII-BG3F62OND5

Paclitaxel

Approved, Vet_approved

Phase 2,Phase 1

33069-62-4

36314

Synonyms:

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

157069-30-2

33069-62-4

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

7 Epi taxol

7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.

7-epi-Paclitaxel

7-Epipaclitaxel

7-Epi-paclitaxel

7-epi-Taxol

7-Epitaxol

7-Epi-taxol

AB00513812

ABI 007

abi-007

ABI007

ABI-007

Abraxane

Abraxane (TN)

Abraxane I.V. Suspension

Abraxis BioScience brand of albumin-bound paclitaxel

AC1L1IOG

AC1L1VJI

AC1L9AVF

AC-675

ACon1_002231

albumin-bound paclitaxel

Ambotz33069-62-4

ANX-513

Anzatax

Asotax

BIDD:PXR0046

Bio-0076

Bio1_000362

Bio1_000851

Bio1_001340

Bio2_000416

Bio2_000896

BMS 181339-01

BMS-181339

BMS-181339-01

BPBio1_000320

BRD-A23723433-001-01-2

BRD-A28746609-001-04-0

BRD-K62008436-001-03-1

Bris taxol

Bristaxol

BSPBio_000290

BSPBio_001152

BSPBio_002614

C07394

C466458

C47H51NO14

Capxol

CCRIS 8143

CHEBI:103439

CHEBI:45863

CHEMBL100910

CHEMBL418410

CHEMBL48

CID36314

CID441276

CID4666

CID6713921

CID6915727

cMAP_000068

CPD-8718

D00491

DB01229

DHP-107

DHP-208

DivK1c_000441

DRG-0190

DTS-301

Ebetaxel

EmPAC

Epitaxol

EU-0101201

Genaxol

Genetaxyl

Genexol

Genexol-PM

HMS1362J13

HMS1568O12

HMS1792J13

HMS1922K08

HMS1990J13

HMS2090D07

HMS2093K15

HMS501G03

HSDB 6839

I06-0014

IDI1_000441

IDI1_002171

Intaxel

KBio1_000441

KBio2_000492

KBio2_002016

KBio2_002509

KBio2_003060

KBio2_004584

KBio2_005077

KBio2_005628

KBio2_007152

KBio2_007645

KBio3_000903

KBio3_000904

KBio3_001834

KBio3_002987

KBioGR_000492

KBioGR_001893

KBioGR_002509

KBioSS_000492

KBioSS_002016

KBioSS_002517

LipoPac

LMPR0104390001

Lopac0_001201

LS-31070

MBT 0206

MEGxp0_001940

Micellar Paclitaxel

Mitotax

MLS000863266

MLS001077297

MLS002154218

MLS002172439

MLS002695976

MolPort-001-742-627

MolPort-003-665-783

MolPort-003-932-365

MPI-5018

nab-paclitaxel

Nanotaxel

NCGC00024995-02

NCGC00024995-03

NCGC00024995-04

NCGC00024995-05

NCGC00024995-06

NCGC00024995-07

NCGC00164367-01

NCGC00164367-02

NCGC00164367-03

nchembio.188-comp1

nchembio.2007.34-comp9

nchembio.215-comp9

nchembio853-comp6

NCI60_000601

Neuro_000060

NINDS_000441

NK 105

Nova-12005

NP-010981

NSC 125973

NSC125973

NSC-125973

NSC358882

OAS-PAC-100

OncoGel

Onxal

Onxol

Onxol, Taxol, Nov-Onxol, Paclitaxel

P1632

Paclical

Pacligel

paclitaxel

Paclitaxel

Paclitaxel (JAN/USP)

Paclitaxel (JAN/USP/INN)

Paclitaxel (Taxol)

Paclitaxel [USAN:INN:BAN]

Paclitaxel, (4 alpha)-isomer

Paxceed

Paxene

Paxoral

Plaxicel

Praxel

Prestwick0_000155

Prestwick1_000155

Prestwick2_000155

Prestwick3_000155

Probes2_000350

QW 8184

S1150_Selleck

S-8184 Paclitaxel Injectable Emulsion

SDCCGMLS-0066823.P001

SDP-013

SMP1_000228

SMR000394086

SMR000857385

SPBio_000943

SPBio_002229

Spectrum_001536

SPECTRUM1503908

Spectrum2_000872

Spectrum3_001057

Spectrum4_001197

Spectrum5_001491

ST50306996

T 7402

T1912_SIGMA

T7191_SIGMA

T7402_SIGMA

TA1

TaxAlbin

Taxol

TAXOL

TAXOL (TN)

Taxol a

Taxol A

Taxol Konzentrat

TAXOL, 10-EPI,

Taxol, bris

Taxol.RTM. (Registered Trademark)

TXL

UNII-P88XT4IS4D

UPCMLD-DP108:001

UPCMLD-DP108:002

Vascular Wrap

weekly paclitaxel

Xorane

Yewtaxan

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Synonyms:

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside

(8S-cis)-10-((3-amino-2,3,6-Trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-amino-2,3,6-Trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

111266-55-8

14-hydroxydaunomycin

14-Hydroxydaunomycin

14-hydroxydaunorubicine

14-Hydroxydaunorubicine

23214-92-8

23257-17-2

24385-08-8

25311-50-6

25316-40-9

25316-40-9 (hydrochloride)

29042-30-6

AC1L1M5T

AC1Q29OJ

adiblastine (hydrochloride salt)

ADM

ADR

adr iablatina (hydrochloride salt)

Adriablastin

Adriablastine

adriablastine (hydrochloride salt)

adriablatina (hydrochloride salt)

Adriacin (hydrochloride salt)

Adriamycin

Adriamycin PFS

Adriamycin PFS (hydrochloride salt)

Adriamycin RDF

Adriamycin RDF (hydrochloride salt)

Adriamycin semiquinone

Adriamycin Semiquinone

Adriblas tina

Adriblastin

Adriblastina

Adriblastina (hydrochloride salt)

Adriblastina (TN)

Adriblastine

adriblatina (hydrochloride salt)

Adrimedac

Aerosolized Doxorubicin

Baxter brand OF doxorubicin hydrochloride

Bedford brand OF doxorubicin hydrochloride

BPBio1_000502

BRD-K92093830-003-04-3

Bristol-myers squibb brand OF doxorubicin hydrochloride

BSPBio_000456

BSPBio_001031

C01661

C27H29NO11

Caelyx

CCRIS 739

Cell pharm brand OF doxorubicin hydrochloride

CHEBI:28748

CHEMBL179

CID31703

Columbia brand OF doxorubicin hydrochloride

Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74

Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120

D03899

DB00997

DM2

Doxil

Doxo

doxo Cell

doxo-Cell

Doxolem

doxorubicin

Doxorubicin

Doxorubicin (USAN/INN)

Doxorubicin [USAN:INN:BAN]

Doxorubicin citrate

Doxorubicin HCl

Doxorubicin hexal

Doxorubicin hydrochloride

Doxorubicin Hydrochloride

Doxorubicin hydrochloride (hydrochloride salt)

Doxorubicin NC

Doxorubicina

Doxorubicina [INN-Spanish]

Doxorubicina ferrer farm

Doxorubicina funk

Doxorubicina tedec

Doxorubicine

Doxorubicine [INN-French]

Doxorubicine baxter

Doxorubicin-hLL1

Doxorubicin-hLL1 conjugate

Doxorubicin-P4/D10

Doxorubicin-P4/D10 conjugate

Doxorubicinum

Doxorubicinum [INN-Latin]

Doxotec

DOX-SL

EINECS 245-495-6

Elan brand OF doxorubicin hydrochloride

Farmablastina (hydrochloride salt)

Farmiblastina

Ferrer brand OF doxorubicin hydrochloride

FI 106

Hexal brand OF doxorubicin hydrochloride

HMS2089H06

HSDB 3070

Hydrochloride, doxorubicin

Hydroxydaunomycin hydrochlor ide (hydrochloride salt)

Hydroxydaunomycin hydrochloride (hydrochloride salt)

Hydroxydaunorubicin

Hydroxydaunorubicin hydrochloride (hydrochloride salt)

JT9100000

Kenfarma brand OF doxorubicin hydrochloride

Lemery brand OF doxorubicin hydrochloride

LMPK13050001

LS-1029

LS-165655

Medac brand OF doxorubicin hydrochloride

MLS000759533

Myocet

NChemBio.2007.10-comp13

nchembio809-comp5

NCI-C01514

NDC 38242-874

Neocorp brand OF doxorubicin hydrochloride

NIOSH/JT9100000

NSC 123127

Onkodox

Onkoworks brand OF doxorubicin hydrochloride

Pfizer brand OF doxorubicin hydrochloride

Prasfarma brand OF doxorubicin hydrochloride

Prestwick0_000438

Prestwick1_000438

Prestwick2_000438

Prestwick3_000438

Probes1_000151

Probes2_000129

RDF Rubex

Resmycin

Ribodoxo

Ribosepharm brand OF doxorubicin hydrochloride

Rubex

Rubex (hydrochloride salt)

SMP1_000106

SPBio_002395

Tedec meiji brand OF doxorubicin hydrochloride

ThermoDox

TLC D-99

Triferric doxorubicin

UNII-80168379AG

Urokit doxo cell

Urokit doxo-cell

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Synonyms:

(-)-Cyclophosphamide

(+-)-Cyclophosphamide

(RS)-Cyclophosphamide

1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine

1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin

2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide

4-Hydroxy-cyclophosphan-mamophosphatide

50-18-0

60007-95-6

6055-19-2 (monohydrate)

75526-90-8

AC1L1EQQ

AI3-26198

Anhydrous cyclophosphamide

Anhydrous, cyclophosphamide

ASTA

Asta B 518

ASTA B518

B 518

B-518

bis(2-Chloroethyl)phosphami de cyclic propanolamide

bis(2-Chloroethyl)phosphamide cyclic propanolamide ester

Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester

BRN 0011744

BSPBio_002099

C 0768

C07888

C7H15Cl2N2O2P

CB 4564

CB-4564

CCRIS 188

CHEBI:4027

CHEMBL32520

CHEMBL88

Ciclofosfamida

Ciclofosfamida [INN-Spanish]

Ciclofosfamide

Ciclophosphamide

Ciclophosphamide [INN]

CID2907

Clafen

Claphene

CPA

CTX

Cycloblastin

Cyclophosphamid

cyclophosphamide

Cyclophosphamide

Cyclophosphamide (anhydrous form)

Cyclophosphamide (anhydrous)

Cyclophosphamide (INN)

Cyclophosphamide (TN)

Cyclophosphamide anhydrous

Cyclophosphamide monohydrate

Cyclophosphamide Monohydrate

Cyclophosphamide Sterile

Cyclophosphamide, (+-)-Isomer

Cyclophosphamide, (R)-isomer

Cyclophosphamide, (S)-isomer

Cyclophosphamides

Cyclophosphamidum

Cyclophosphamidum [INN-Latin]

Cyclophosphan

Cyclophosphane

Cyclophosphanum

Cyclophosphoramide

Cyclostin

Cyklofosfamid

Cyklofosfamid [Czech]

Cytophosphan

Cytophosphane

Cytoxan

Cytoxan (TN)

Cytoxan Lyoph

D,L-Cyclophosphamide

D07760

DB00531

DivK1c_000246

EINECS 200-015-4

Endoxan

Endoxan R

Endoxana

Endoxanal

Endoxan-Asta

Endoxane

Enduxan

EU-0100238

Genoxal

Hexadrin

HMS2090A12

HSDB 3047

IDI1_000246

KBio1_000246

KBio2_001338

KBio2_003906

KBio2_006474

KBio3_001319

KBioGR_000888

KBioSS_001338

Ledoxina

Lopac0_000238

Lopac-C-0768

LS-1302

LS-99787

Lyophilized Cytoxan

Mitoxan

MolPort-001-783-420

Monohydrate, cyclophosphamide

N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

NCGC00015209-01

NCGC00015209-03

NCGC00015209-06

NCGC00091741-02

NCGC00091741-03

NCI60_002097

NCI-C04900

Neosar

NINDS_000246

NSC 26271

NSC26271

NSC-26271

NSC273033

NSC273034

Occupation, cyclophosphamide exposure

Procytox

RCRA waste no. U058

Rcra waste number U058

Rcra Waste Number U058

Revimmune

S1217_Selleck

Semdoxan

Sendoxan

Senduxan

SK 20501

SPBio_001071

Spectrum_000858

Spectrum2_001146

Spectrum3_000370

Spectrum4_000304

Spectrum5_000795

STK177249

STOCK2S-91217

UNII-6UXW23996M

WLN: T6MPOTJ BO BN2G2G

Zyklophosphamid

Zyklophosphamid [German]

Zoledronic acid

Approved

Phase 2

118072-93-8

68740

Synonyms:

(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate

(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid

(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid

(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid

(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate

(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid

(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid

(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate

[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)

118072-93-8

2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid

2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid

2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid

AC-1092

AC1L2ACJ

AC1Q6RN3

Aclasta

AKOS005145739

Anhydrous Zoledronic Acid

BIDD:GT0292

BIDD:PXR0134

Bio-0112

Bisphosphonate 3

C088658

CGP 42446

CGP 42'446

CGP 42446A

CGP-42446

CGP-42'446

CHEBI:46557

CHEMBL924

CID68740

D08689

DB00399

FT-0082657

HMS2089O09

I06-0710

KS-1132

LS-181815

MolPort-002-885-874

MolPort-003-850-890

NCGC00159521-02

NCGC00159521-03

Novartis brand of zoledronic acid

Novartis brand OF zoledronic acid

NSC721517

Reclast

Reclast (TN)

S00092

S1314_Selleck

UNII-70HZ18PH24

Zol

ZOL

Zoledronate

Zoledronic acid

Zoledronic acid (INN)

Zoledronic acid [USAN:INN]

Zoledronic Acid Anhydrous

Zoledronic Acid, Anhydrous

Zometa

Zometa (Novartis)

Zometa (TN)

Zometa Concentrate

Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid

Doxil

Approved June 1999

Phase 2

31703

Albumin-Bound Paclitaxel

Phase 2,Phase 1

Antimitotic Agents

Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 2,Phase 1

Alkylating Agents

Phase 2

Topoisomerase Inhibitors

Phase 2

Anti-Bacterial Agents

Phase 2

Antibiotics, Antitubercular

Phase 2

Immunosuppressive Agents

Phase 2

Antirheumatic Agents

Phase 2

Antineoplastic Agents, Alkylating

Phase 2

Diphosphonates

Phase 2

Bone Density Conservation Agents

Phase 2

Veliparib

Investigational

Phase 1

912444-00-9

11960529

Poly(ADP-ribose) Polymerase Inhibitors

Phase 1

Menthol

Approved

Not Applicable

2216-51-5

16666

Synonyms:

(&#8722

(-)-(1R,3R,4S)-Menthol

(-)-menthol

()-Menthol

(-)-Menthyl alcohol

(-)-p-Menthan-3-ol

(-)-trans-p-Menthan-cis-ol

(-)-trans-P-Menthan-cis-ol

(+-)-(1R*,3R*,4S*)-Menthol

(+-)-Menthol

(+)-Neo-menthol

(+)-p-Menthan-3-ol

(+/-)-Menthol

(+/-)-p-Menthan-3-ol

(1a,2b,5a)-5-Methyl-2(1-methylethyl)cyclohexanol

(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol

(1R-(1-a,2-b,5-a))-5-Methyl-2-(1-methylethyl)cyclohexanol

(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol

(1R-(1-α,2-β,5-α))-5-methyl-2-(1-methylethyl)cyclohexanol

(1R)-(-)-Menthol

(1r,2s,5r)-(-)-menthol

(1R,2S,5R)-(-)-Menthol

(1R,2S,5R)-Menthol

(1R,3R,4S)-(-)-Menthol

(1R,3R,4S)-(-)-MENTHOL

(1S, 2S, 5R)-(+)-Neomenthol

(1S,2R,5R)-(+)-Isomenthol

(1S,2R,5S)-(+)-Menthol

(1S,2R,5S)-Menthol

(1α,2β,5α)-5-methyl-2(1-methylethyl)cyclohexanol

(L)-MENTHOL

(r)-(-)-menthol

(R)-(-)-Menthol

)-Menthol

1490-04-6

15356-60-2

15356-70-4

15785_RIEDEL

15785_SIAL

19863P

1-Menthol

20747-49-3

2216-51-5

2-Isopropyl-5-methylcyclohexanol

3-p-Menthol

491-02-1

4-Isopropyl-1-methylcyclohexan-3-ol

551376_ALDRICH

551376_FLUKA

588733_ALDRICH

5-Methyl-2-(1-methylethyl)cyclohexanol

5-Methyl-2-(1-methylethyl)-cyclohexanol

5-methyl-2-(propan-2-yl)cyclohexanol

5-methyl-2-propan-2-ylcyclohexan-1-ol

5-Methyl-2-propan-2-ylcyclohexan-1-ol

613290_ALDRICH

613290_FLUKA

63660_FLUKA

63670_ALDRICH

63670_FLUKA

63975-60-0

6C6A4A8C-A054-468C-A1F0-F29E39838CF2

89-78-1

98167-53-4

AC1L1B2E

AC1L28FR

AC1Q1NQ2

AC1Q2QQM

AI3-08161

AI3-52408

AKOS000119740

AR-1J3337

BB_NC-0057

BRN 1902288

BRN 3194263

BSPBio_003062

C00400

C10H20O

Caswell No. 540

CCRIS 3728

CCRIS 375

CCRIS 4666

CCRIS 9231

CHEBI:15409

CHEBI:545611

CHEMBL256087

CHEMBL470670

CID1254

CID16666

cis-1 ,3-trans-1,4-(+-)-menthol

cis-1,3-trans-1,4-(+-)-menthol

D-(-)-Menthol

d,l-Menthol

D00064

D008610

D04849

D04918

DB00825

DivK1c_000820

dl-3-p-Menthanol

dl-Menthol

dl-Menthol (JP15)

d-Menthol

d-Neomenthol

D-p-Menthan-3-ol

EINECS 201-939-0

EINECS 207-724-8

EINECS 216-074-4

EINECS 218-690-9

EINECS 239-387-8

EINECS 239-388-3

EPA Pesticide Chemical Code 051601

FEMA No. 2665

Fisherman's friend lozenges

Fisherman's friend lozenges (TN)

Headache crystals

Hexahydrothymol

HMS1922G13

HMS2092L14

HMS502I22

HSDB 5662

HSDB 593

I06-1216

I14-7371

IDI1_000820

KBio1_000820

KBio2_000785

KBio2_003353

KBio2_005921

KBio3_002562

KBioSS_000785

Kerasal

l-(-)-Menthol

L-(-)-menthol

L-(-)-Menthol

Levomenthol

Levomenthol [INN:BAN]

Levomentholum

Levomentholum [INN-Latin]

Levomentol

l-Menthol

L-menthol

L-Menthol

l-Menthol (JP15)

l-Menthol (natural)

l-Menthol (TN)

LMPR0102090001

LS-2353

LS-57201

LS-886

LS-89531

LS-89533

M0321

M0545

M2772_SIAL

Menthacamphor

MENTHOL

--MENTHOL

Menthol (USP)

Menthol (VAN)

Menthol natural

Menthol natural, brazilian

Menthol racemic

Menthol racemique

Menthol racemique [French]

Menthol solution

Menthol, (1alpha,2beta,5alpha)-isomer

Menthol, (1alpha,2beta,5alpha)-Isomer

Menthomenthol

Menthyl alcohol

MLS002207256

MolPort-000-849-729

MolPort-001-793-392

NCGC00159382-02

NCGC00159382-03

NCGC00164247-01

NCGC00164247-02

nchembio862-comp1

NCI-C50000

Neoisomenthol

NINDS_000820

NOOLISFMXDJSKH-KXUCPTDWBX

NSC 2603

NSC 62788

NSC2603

NSC62788

Peppermint camphor

p-Menthan-3-ol

P-Menthan-3-ol

Racementhol

Racementhol [INN:BAN]

Racementholum

Racementholum [INN-Latin]

Racementol

Racementol [INN-Spanish]

Racemic menthol

RACEMIC MENTHOL U.S.P.

rac-Menthol

Robitussin Cough Drops

SDCCGMLS-0066659.P001

SMR001306785

SPBio_000869

Spectrum_000305

SPECTRUM1503134

Spectrum2_000855

Spectrum3_001561

Spectrum5_001060

STK802468

Tra-kill tracheal mite killer

U.S.p. menthol

U.S.P. Menthol

UNII-BZ1R15MTK7

UNII-L7T10EIP3A

UNII-YS08XHA860

W266507_ALDRICH

W266523_ALDRICH

W266590_ALDRICH

WLN: L6TJ AY1&1 BQ D1

WLN: L6TJ AY1&1 DQ D1 -L

ZINC01482164

Ethanol

Approved

Not Applicable

64-17-5

702

Synonyms:

(C6-C9)Alkyl alcohol

[CH2Me(OH)]

[OEtH]

02483_FLUKA

02851_FLUKA

02853_FLUKA

02854_FLUKA

02855_FLUKA

02856_FLUKA

02856_SIAL

02857_FLUKA

02857_SIAL

02858_FLUKA

02858_SIAL

02860_FLUKA

02865_FLUKA

02865_SIAL

02870_FLUKA

02870_SIAL

02875_FLUKA

02877_FLUKA

02878_FLUKA

02882_FLUKA

02882_SIAL

02883_FLUKA

02884_FLUKA

02890_FLUKA

02890_SIAL

02891_FLUKA

02891_SIAL

100C.NPA

121182-78-3

187380_ALDRICH

187380_SIAL

1-Hydroxyethane

24102_RIEDEL

24102_SIAL

24103_RIEDEL

24103_SIAL

24105_RIEDEL

24105_SIAL

24106_RIEDEL

24106_SIAL

24194_RIEDEL

24194_SIAL

245119_ALDRICH

245119_SIAL

270741_ALDRICH

270741_SIAL

277649_ALDRICH

277649_SIAL

2858_SIGMA

29221_FLUKA

32205_RIEDEL

32205_SIAL

32221_RIEDEL

32221_SIAL

32294_RIEDEL

32294_SIAL

34870_SIAL

34963_RIEDEL

39278_FLUKA

40210_ALDRICH

40210_RIEDEL

41322_FLUKA

458600_ALDRICH

458600_SIAL

459828_ALDRICH

459828_SIAL

459836_ALDRICH

459836_SIAL

459844_SIAL

48075_SUPELCO

493511_SIAL

493538_ALDRICH

493538_SIAL

493546_ALDRICH

493546_SIAL

64-17-5

676829_SIAL

68475-56-9

71076-86-3

71329-38-9

8000-16-6

8024-45-1

absolute alcohol

Absolute alcohol

Absolute Alcohol

Absolute ethanol

Absolute Ethanol

Absolute ethyl alcohol

AC1L19TW

AC1Q31MM

Aethanol

Aethanol [German]

Aethylalkohol

AHD 2000

AI3-01706

Alcare hand degermer

Alcare Hand Degermer

alcohol

Alcohol

Alcohol (ethyl)

Alcohol (USP)

Alcohol [USP]

ALCOHOL 5% IN D5-W

Alcohol anhydrous

Alcohol Anhydrous

Alcohol dehydrated

Alcohol denatured

alcohol etilico

Alcohol etilico

Alcohol etílico

Alcohol, absolute

Alcohol, Absolute

Alcohol, anhydrous

Alcohol, dehydrated

Alcohol, Dehydrated

Alcohol, denatured

Alcohol, diluted

Alcohol, Diluted

Alcohol, ethyl

Alcohol, grain

Alcohol, Grain

Alcohols

Alcohols, C1-3

Alcohols, C30

Alcohols, C6-9

Alcool ethylique

Alcool Ethylique

Alcool éthylique

Alcool etilico

Alcool Etilico

Algrain

Alkohol

Alkohol [German]

Alkoholu etylowego

Alkoholu Etylowego

Aminoethanol

Anhydrol

Anhydrol PM 4085

Anhydrous alcohol

Anhydrous ethanol

Äthanol

Äthylalkohol

Beta-Aminoethanol

Beta-Aminoethyl Alcohol

Beta-Ethanolamine

Beta-Hydroxyethylamine

bmse000297

C00469

C2H5OH

C2H6O

Caswell No. 426

Caswell No. 430

CCRIS 945

CDA 19

CDA 19-200

CHEBI:16236

CHEMBL545

CID702

Colamine

Cologne spirit

Cologne Spirit

Cologne spirits

D000431

D00068

DB00898

Dehydrated alcohol

Dehydrated ethanol

Dehydrated Ethanol

Denatured alcohol

Denatured Alcohol

Denatured Alcohol Cd-10

Denatured Alcohol Cd-5

Denatured Alcohol Cd-5a

Denatured Alcohol Sd-1

Denatured Alcohol Sd-13a

Denatured Alcohol Sd-17

Denatured Alcohol Sd-23a

Denatured Alcohol Sd-28

Denatured Alcohol Sd-30

Denatured Alcohol Sd-39b

Denatured Alcohol Sd-39c

Denatured Alcohol Sd-3a

Denatured Alcohol Sd-40m

Denatured ethanol

Denatured Ethanol

Desinfektol el

Desinfektol EL

Diluted alcohol

Distilled spirits

E2385_SIGMA

E7023_ALDRICH

E7023_SIAL

E7148_ALDRICH

E7148_SIAL

E7517_SIGMA

EINECS 200-578-6

EINECS 270-649-4

Envision Conditioner Pdd 9020

EOH

EOX

Esumiru WK 88

ETA

etanol

Etanol

Etanolo

Etanolo [Italian]

ethanol

éthanol

Ethanol (9CI)

Ethanol [JAN]

Ethanol 200 proof

Ethanol 200 Proof

Ethanol Absolute

Ethanol Absolute Bp

Ethanol Anhydrous

Ethanol Extra Pure

Ethanol solution

Ethanol Vapor

Ethanol, Silent Spirit

Ethanol, undenatured

Ethanolum anhydricum

Ethicap

Ethyl alc

ethyl alcohol

Ethyl alcohol

Ethyl Alcohol

Ethyl Alcohol & Water, 10%

Ethyl Alcohol & Water, 20%

Ethyl Alcohol & Water, 30%

Ethyl Alcohol & Water, 40%

Ethyl Alcohol & Water, 5%

Ethyl Alcohol & Water, 50%

Ethyl Alcohol & Water, 60%

Ethyl Alcohol & Water, 70%

Ethyl Alcohol & Water, 80%

Ethyl Alcohol & Water, 95%

Ethyl Alcohol & Water, 96%

Ethyl alcohol anhydrous

Ethyl Alcohol Anhydrous

Ethyl alcohol in alcoholic beverages

Ethyl alcohol usp

Ethyl Alcohol, Anhydrous

Ethyl Alcohol, Denatured

Ethyl hydrate

Ethyl Hydrate

Ethyl hydroxide

Ethyl Hydroxide

Ethylalcohol

Ethylalcohol [Dutch]

Ethylol

Ethylolamine

Ethyloxy Group

EtOH

Etylowy alkohol

FEMA No. 2419

FEMA Number 2419

Fermentation alcohol

Glycinol

grain alcohol

Grain alcohol

Hinetoless

HSDB 531

HSDB 82

Hydroxyethane

HYDROXYETHYL GROUP

I14-12648

IMS 99

Infinity pure

Infinity Pure

Jaysol

Jaysol S

LS-1539

LTBB002977

Lux

Methylated spirit

Methylated Spirit Mineralised

Methylcarbinol

Molasses alcohol

MolPort-001-785-844

NCGC00091458-01

nchem.651-comp3c

nchembio.552-comp10

nchembio.94-comp20

NCI-C03134

NSC 85228

NSC85228

Oxydimethylene Group

potato Alcohol

Potato alcohol

Punctilious ethyl alcohol

Pyro

QMHAIh@

Reagent Alcohol

Ru-Tuss Expectorant

SDA 3A

SDA 40-2

SDM No. 37

Sekundasprit

Silent spirit

Spirit

Spirits of wine

Spirits OF wine

spiritus vini

Spiritus vini

Spirt

SY Fresh M

Synasol

Tecsol

Tecsol C

Thanol

Thiofaco M-50

Undenatured ethanol

UNII-3K9958V90M

USAF EK-1597

WLN: Q2

Interventional clinical trials:

(show all 40)

#	Name	Status	NCT ID	Phase	Drugs
1	Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study	Completed	NCT02562170	Phase 4
2	Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers	Recruiting	NCT03162276	Phase 3
3	Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers	Completed	NCT01367639	Phase 2
4	Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer	Completed	NCT01333748	Phase 2
5	The Women Choosing Surgical Prevention (WISP) Trial	Recruiting	NCT02760849	Phase 2
6	Neoadjuvant Carboplatin in Triple Negative Breast Cancer	Recruiting	NCT02978495	Phase 2	Doxorubicin;Carboplatin;Paclitaxel;Cyclophosphamide
7	A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer	Recruiting	NCT02203513	Phase 2	LY2606368
8	Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries	Active, not recruiting	NCT00305695	Phase 2	Zoledronic Acid
9	Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer	Completed	NCT00535119	Phase 1	Carboplatin;Paclitaxel;Veliparib
10	Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy	Completed	NCT00892736	Phase 1	Veliparib
11	Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk	Unknown status	NCT02705924	Not Applicable
12	Hypodontia and Ovarian Cancer	Unknown status	NCT01470235
13	Statewide Communication to Reach Diverse Low Income Women	Completed	NCT02956681	Not Applicable
14	Cancer Genetics Hereditary Cancer Panel Testing	Completed	NCT02324062
15	Telemedicine vs. Face-to-Face Cancer Genetic Counseling	Completed	NCT00609505	Not Applicable
16	Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer	Completed	NCT02786147
17	Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)	Completed	NCT00829959
18	Risk Education and Assessment for Cancer Heredity	Completed	NCT01346761	Not Applicable
19	Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer	Recruiting	NCT03075540	Not Applicable
20	Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling	Recruiting	NCT03225170	Not Applicable
21	Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment	Recruiting	NCT03511690	Not Applicable
22	Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry	Recruiting	NCT02302742
23	Inherited Susceptible Genes Among Epithelial Ovarian Cancer	Recruiting	NCT03015376
24	Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers	Recruiting	NCT02516540	Not Applicable
25	Risk-Reducing Surgeries for Hereditary Ovarian Cancer	Recruiting	NCT03294343	Not Applicable
26	Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.	Recruiting	NCT03246841	Not Applicable
27	Decision Support for BRCA Testing in Ethnically Diverse Women	Recruiting	NCT03470402	Not Applicable
28	Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland	Recruiting	NCT03124212
29	Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients	Recruiting	NCT01789684	Not Applicable
30	Familial Cancer Registry and DNA Bank	Recruiting	NCT02083224
31	Genetic Risk: Whether, When, and How to Tell Adolescents	Recruiting	NCT03421327
32	Familial Investigations of Childhood Cancer Predisposition	Recruiting	NCT03050268
33	Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers	Active, not recruiting	NCT02087592	Not Applicable
34	Radical Fimbriectomy for Young BRCA Mutation Carriers	Active, not recruiting	NCT01608074	Not Applicable
35	Genetic Counseling for Breast Cancer Survivors (GC for BC)	Active, not recruiting	NCT02451735	Not Applicable
36	Women at Risk of Breast Cancer and OLFM4	Not yet recruiting	NCT02653105	Not Applicable
37	Cancer Health Assessments Reaching Many	Not yet recruiting	NCT03426878	Not Applicable
38	Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199	Not yet recruiting	NCT01445275
39	Blood Markers of Early Pancreas Cancer	Not yet recruiting	NCT03568630
40	Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans	Terminated	NCT01374685

Search NIH Clinical Center for Hereditary Breast Ovarian Cancer Syndrome

Cochrane evidence based reviews: hereditary breast and ovarian cancer syndrome

Sources

Genetic Tests for Hereditary Breast Ovarian Cancer Syndrome

Genetic tests related to Hereditary Breast Ovarian Cancer Syndrome:

#	Genetic test	Affiliating Genes
1	Hereditary Breast and Ovarian Cancer Syndrome ²⁹	BRCA1 BRCA2

Sources

Anatomical Context for Hereditary Breast Ovarian Cancer Syndrome

MalaCards organs/tissues related to Hereditary Breast Ovarian Cancer Syndrome:

⁴¹

Breast, Testes, Ovary, Bone, Prostate, Pancreas

Sources

Publications for Hereditary Breast Ovarian Cancer Syndrome

Articles related to Hereditary Breast Ovarian Cancer Syndrome:

(show all 20)

#	Title	Authors	Year
1	Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. ( 28832484 )		2017
2	Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome. ( 28488140 )	Concolino P....Capoluongo E.	2017
3	Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome. ( 29273311 )	Shaw J....Hardcastle S.J.	2017
4	MA1llerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery. ( 26875157 )	Casey M.J....Colanta A.B.	2016
5	Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome. ( 26943589 )	Menendez J.A....AlarcA^n T.	2016
6	Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds: report from the creighton university hereditary cancer registry with review of the implications. ( 25756400 )	Casey M.J....Stacey M.	2015
7	Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. ( 25549704 )	Agarwal R....Subbiah V.	2014
8	Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists. ( 24021253 )	Meaney-Delman D....Bellcross C.A.	2013
9	Hereditary breast ovarian cancer syndromes in the Maritimes. ( 20181317 )	O'Quinn C....Kieser K.	2010
10	Hereditary breast-ovarian cancer syndrome in Russia. ( 22649661 )	Sokolenko A.P....Imyanitov E.N.	2010
11	Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. ( 19292801 )	Ozanne E.M....Hughes K.S.	2009
12	Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. ( 18410690 )	Batista L.I....Meric-Bernstam F.	2008
13	Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. ( 17898808 )	Roukos D.H....Briasoulis E.	2007
14	High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic. ( 17561994 )	Vasickova P....Foretova L.	2007
15	Re: &quot;Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations&quot;. ( 16188301 )	Olivier R.I....van Beurden M.	2005
16	Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. ( 15863145 )	Casey M.J....Lynch H.T.	2005
17	Prophylactic surgery in hereditary breast/ovarian cancer syndrome. ( 12886864 )	Levine D.A....Gemignani M.L.	2003
18	Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? ( 11104623 )	Goshen R....Narod S.A.	2000
19	Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. ( 10985881 )	Casey M.J....Watson P.	2000
20	Insurance adjudication favoring prophylactic surgery in hereditary breast-ovarian cancer syndrome. ( 7705697 )	Lynch H.T....Lynch J.	1995

Sources

Genes for Hereditary Breast Ovarian Cancer Syndrome

Genes related to Hereditary Breast Ovarian Cancer Syndrome (14 elite genes):

(show all 21)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	BRCA1	BRCA1, DNA Repair Associated	Protein Coding	900.77	Pathogenic ⁶ Causative germline mutation (loss of function) ⁵⁹ Genetic Tests ²⁹ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	BRCA2	BRCA2, DNA Repair Associated	Protein Coding	900.6	Pathogenic ⁶ Causative germline mutation (loss of function) ⁵⁹ Genetic Tests ²⁹ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	RAD51C	RAD51 Paralog C	Protein Coding	788.82	Pathogenic ⁶ Causative germline mutation ⁵⁹ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
4	RAD51D	RAD51 Paralog D	Protein Coding	750	Pathogenic ⁶ Causative germline mutation ⁵⁹
5	PALB2	Partner And Localizer Of BRCA2	Protein Coding	464.39	Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ Candidate gene tested ⁵⁹ DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
6	CHEK2	Checkpoint Kinase 2	Protein Coding	450	Pathogenic ⁶ Risk factor ⁶ Candidate gene tested ⁵⁹
7	BARD1	BRCA1 Associated RING Domain 1	Protein Coding	450	Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ Candidate gene tested ⁵⁹
8	BRIP1	BRCA1 Interacting Protein C-Terminal Helicase 1	Protein Coding	450	Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ Candidate gene tested ⁵⁹
9	NBN	Nibrin	Protein Coding	50	Pathogenic/Likely pathogenic ⁶ Candidate gene tested ⁵⁹
10	TP53	Tumor Protein P53	Protein Coding	39.56	Candidate gene tested ⁵⁹ DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
11	ATM	ATM Serine/Threonine Kinase	Protein Coding	38.65	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
12	PTEN	Phosphatase And Tensin Homolog	Protein Coding	25	Candidate gene tested ⁵⁹
13	RAD50	RAD50 Double Strand Break Repair Protein	Protein Coding	25	Candidate gene tested ⁵⁹
14	MRE11	MRE11 Homolog, Double Strand Break Repair Nuclease	Protein Coding	25	Candidate gene tested ⁵⁹
15	RAD51	RAD51 Recombinase	Protein Coding	25	Candidate gene tested ⁵⁹
16	XRCC2	X-Ray Repair Cross Complementing 2	Protein Coding	16.52	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
17	PMS1	PMS1 Homolog 1, Mismatch Repair System Component	Protein Coding	15.53	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
18	MLH1	MutL Homolog 1	Protein Coding	14.64	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
19	MSH2	MutS Homolog 2	Protein Coding	14.53	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
20	PRSS1	Serine Protease 1	Protein Coding	14.4	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
21	STK11	Serine/Threonine Kinase 11	Protein Coding	14.26	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)

Sources

Variations for Hereditary Breast Ovarian Cancer Syndrome

ClinVar genetic disease variations for Hereditary Breast Ovarian Cancer Syndrome:

⁶

(show top 50) (show all 8830)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	CHEK2	NM_007194.3(CHEK2): c.1283C> T (p.Ser428Phe)	single nucleotide variant	risk factor	rs137853011	GRCh37	Chromosome 22, 29091207: 29091207
2	CHEK2	NM_007194.3(CHEK2): c.1283C> T (p.Ser428Phe)	single nucleotide variant	risk factor	rs137853011	GRCh38	Chromosome 22, 28695219: 28695219
3	BRCA2	NM_000059.3(BRCA2): c.7004_7007+2delTTCGGT	deletion	Pathogenic	rs397507890	GRCh37	Chromosome 13, 32921030: 32921035
4	BRCA2	NM_000059.3(BRCA2): c.7004_7007+2delTTCGGT	deletion	Pathogenic	rs397507890	GRCh38	Chromosome 13, 32346893: 32346898
5	BRCA2	NM_000059.3(BRCA2): c.6275_6276delTT (p.Leu2092Profs)	deletion	Pathogenic	rs11571658	GRCh37	Chromosome 13, 32914767: 32914768
6	BRCA2	NM_000059.3(BRCA2): c.6275_6276delTT (p.Leu2092Profs)	deletion	Pathogenic	rs11571658	GRCh38	Chromosome 13, 32340630: 32340631
7	BRCA2	NM_000059.3(BRCA2): c.6591_6592delTG (p.Glu2198Asnfs)	deletion	Pathogenic	rs80359605	GRCh37	Chromosome 13, 32915083: 32915084
8	BRCA2	NM_000059.3(BRCA2): c.6591_6592delTG (p.Glu2198Asnfs)	deletion	Pathogenic	rs80359605	GRCh38	Chromosome 13, 32340946: 32340947
9	BRCA2	NM_000059.3(BRCA2): c.5722_5723delCT (p.Leu1908Argfs)	deletion	Pathogenic	rs80359530	GRCh37	Chromosome 13, 32914214: 32914215
10	BRCA2	NM_000059.3(BRCA2): c.5722_5723delCT (p.Leu1908Argfs)	deletion	Pathogenic	rs80359530	GRCh38	Chromosome 13, 32340077: 32340078
11	BRCA2	NM_000059.3(BRCA2): c.2808_2811del (p.Ala938Profs)	deletion	Pathogenic	rs80359351	GRCh37	Chromosome 13, 32911300: 32911303
12	BRCA2	NM_000059.3(BRCA2): c.2808_2811del (p.Ala938Profs)	deletion	Pathogenic	rs80359351	GRCh38	Chromosome 13, 32337163: 32337166
13	BRCA2	NM_000059.3(BRCA2): c.5946delT (p.Ser1982Argfs)	deletion	Pathogenic	rs80359550	GRCh37	Chromosome 13, 32914438: 32914438
14	BRCA2	NM_000059.3(BRCA2): c.5946delT (p.Ser1982Argfs)	deletion	Pathogenic	rs80359550	GRCh38	Chromosome 13, 32340301: 32340301
15	BRCA2	NM_000059.3(BRCA2): c.771_775delTCAAA (p.Asn257Lysfs)	deletion	Pathogenic	rs80359671	GRCh37	Chromosome 13, 32905145: 32905149
16	BRCA2	NM_000059.3(BRCA2): c.771_775delTCAAA (p.Asn257Lysfs)	deletion	Pathogenic	rs80359671	GRCh38	Chromosome 13, 32331008: 32331012
17	BRCA2	NM_000059.3(BRCA2): c.8537_8538delAG (p.Glu2846Glyfs)	deletion	Pathogenic	rs80359714	GRCh37	Chromosome 13, 32945142: 32945143
18	BRCA2	NM_000059.3(BRCA2): c.8537_8538delAG (p.Glu2846Glyfs)	deletion	Pathogenic	rs80359714	GRCh38	Chromosome 13, 32371005: 32371006
19	BRCA2	NM_000059.3(BRCA2): c.658_659delGT (p.Val220Ilefs)	deletion	Pathogenic	rs80359604	GRCh37	Chromosome 13, 32903606: 32903607
20	BRCA2	NM_000059.3(BRCA2): c.658_659delGT (p.Val220Ilefs)	deletion	Pathogenic	rs80359604	GRCh38	Chromosome 13, 32329469: 32329470
21	BRCA2	NM_000059.3(BRCA2): c.4648G> T (p.Glu1550Ter)	single nucleotide variant	Pathogenic	rs80358695	GRCh37	Chromosome 13, 32913140: 32913140
22	BRCA2	NM_000059.3(BRCA2): c.4648G> T (p.Glu1550Ter)	single nucleotide variant	Pathogenic	rs80358695	GRCh38	Chromosome 13, 32339003: 32339003
23	BRCA2	NM_000059.3(BRCA2): c.5645C> G (p.Ser1882Ter)	single nucleotide variant	Pathogenic	rs80358785	GRCh37	Chromosome 13, 32914137: 32914137
24	BRCA2	NM_000059.3(BRCA2): c.5645C> G (p.Ser1882Ter)	single nucleotide variant	Pathogenic	rs80358785	GRCh38	Chromosome 13, 32340000: 32340000
25	BRCA2	NM_000059.3(BRCA2): c.9196C> T (p.Gln3066Ter)	single nucleotide variant	Pathogenic	rs80359180	GRCh37	Chromosome 13, 32954222: 32954222
26	BRCA2	NM_000059.3(BRCA2): c.9196C> T (p.Gln3066Ter)	single nucleotide variant	Pathogenic	rs80359180	GRCh38	Chromosome 13, 32380085: 32380085
27	BRCA2	NM_000059.3(BRCA2): c.631+1G> A	single nucleotide variant	Pathogenic/Likely pathogenic	rs81002897	GRCh37	Chromosome 13, 32900751: 32900751
28	BRCA2	NM_000059.3(BRCA2): c.631+1G> A	single nucleotide variant	Pathogenic/Likely pathogenic	rs81002897	GRCh38	Chromosome 13, 32326614: 32326614
29	BRCA2	NM_000059.3(BRCA2): c.631+2T> G	single nucleotide variant	Pathogenic	rs81002899	GRCh37	Chromosome 13, 32900752: 32900752
30	BRCA2	NM_000059.3(BRCA2): c.631+2T> G	single nucleotide variant	Pathogenic	rs81002899	GRCh38	Chromosome 13, 32326615: 32326615
31	BRCA1	NM_007294.3(BRCA1): c.190T> G (p.Cys64Gly)	single nucleotide variant	Pathogenic	rs80357064	GRCh37	Chromosome 17, 41258495: 41258495
32	BRCA1	NM_007294.3(BRCA1): c.190T> G (p.Cys64Gly)	single nucleotide variant	Pathogenic	rs80357064	GRCh38	Chromosome 17, 43106478: 43106478
33	BRCA1	NM_007294.3(BRCA1): c.181T> G (p.Cys61Gly)	single nucleotide variant	Pathogenic	rs28897672	GRCh37	Chromosome 17, 41258504: 41258504
34	BRCA1	NM_007294.3(BRCA1): c.181T> G (p.Cys61Gly)	single nucleotide variant	Pathogenic	rs28897672	GRCh38	Chromosome 17, 43106487: 43106487
35	BRCA1	NM_007294.3(BRCA1): c.68_69delAG (p.Glu23Valfs)	deletion	Pathogenic	rs80357783	GRCh37	Chromosome 17, 41276047: 41276048
36	BRCA1	NM_007294.3(BRCA1): c.68_69delAG (p.Glu23Valfs)	deletion	Pathogenic	rs80357783	GRCh38	Chromosome 17, 43124030: 43124031
37	BRCA1	NM_007294.3(BRCA1): c.1175_1214del40 (p.Leu392Glnfs)	deletion	Pathogenic	rs80359874	GRCh37	Chromosome 17, 41246334: 41246373
38	BRCA1	NM_007294.3(BRCA1): c.1175_1214del40 (p.Leu392Glnfs)	deletion	Pathogenic	rs80359874	GRCh38	Chromosome 17, 43094317: 43094356
39	BRCA1	NM_007294.3(BRCA1): c.2296_2297delAG (p.Ser766Terfs)	deletion	Pathogenic	rs80357780	GRCh37	Chromosome 17, 41245251: 41245252
40	BRCA1	NM_007294.3(BRCA1): c.2296_2297delAG (p.Ser766Terfs)	deletion	Pathogenic	rs80357780	GRCh38	Chromosome 17, 43093234: 43093235
41	BRCA1	NM_007294.3(BRCA1): c.2681_2682delAA (p.Lys894Thrfs)	deletion	Pathogenic	rs80357971	GRCh37	Chromosome 17, 41244866: 41244867
42	BRCA1	NM_007294.3(BRCA1): c.2681_2682delAA (p.Lys894Thrfs)	deletion	Pathogenic	rs80357971	GRCh38	Chromosome 17, 43092849: 43092850
43	BRCA1	NM_007294.3(BRCA1): c.3005delA (p.Asn1002Thrfs)	deletion	Pathogenic	rs80357601	GRCh38	Chromosome 17, 43092526: 43092526
44	BRCA1	NM_007294.3(BRCA1): c.3005delA (p.Asn1002Thrfs)	deletion	Pathogenic	rs80357601	GRCh37	Chromosome 17, 41244543: 41244543
45	BRCA1	NM_007294.3(BRCA1): c.3607C> T (p.Arg1203Ter)	single nucleotide variant	Pathogenic	rs62625308	GRCh37	Chromosome 17, 41243941: 41243941
46	BRCA1	NM_007294.3(BRCA1): c.3607C> T (p.Arg1203Ter)	single nucleotide variant	Pathogenic	rs62625308	GRCh38	Chromosome 17, 43091924: 43091924
47	BRCA1	NM_007294.3(BRCA1): c.3748G> T (p.Glu1250Ter)	single nucleotide variant	Pathogenic	rs28897686	GRCh37	Chromosome 17, 41243800: 41243800
48	BRCA1	NM_007294.3(BRCA1): c.3748G> T (p.Glu1250Ter)	single nucleotide variant	Pathogenic	rs28897686	GRCh38	Chromosome 17, 43091783: 43091783
49	BRCA1	NM_007294.3(BRCA1): c.3756_3759delGTCT (p.Ser1253Argfs)	deletion	Pathogenic	rs80357868	GRCh37	Chromosome 17, 41243789: 41243792
50	BRCA1	NM_007294.3(BRCA1): c.3756_3759delGTCT (p.Ser1253Argfs)	deletion	Pathogenic	rs80357868	GRCh38	Chromosome 17, 43091772: 43091775

Sources

Expression for Hereditary Breast Ovarian Cancer Syndrome

Search GEO for disease gene expression data for Hereditary Breast Ovarian Cancer Syndrome.

Sources

Pathways for Hereditary Breast Ovarian Cancer Syndrome

Pathways related to Hereditary Breast Ovarian Cancer Syndrome according to GeneCards Suite gene sharing:

(show all 44)

#	Super pathways	Score	Top Affiliating Genes
1	Gene Expression ⁶⁶ Show member pathways Generic Transcription Pathway ⁶⁶	13.87	ATM BARD1 BRCA1 BRIP1 CHEK2 MLH1
2	Cell Cycle, Mitotic ⁶⁶ Show member pathways Cell Cycle ⁶⁶ M Phase ⁶⁶	13.54	ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
3	DNA Double-Strand Break Repair ⁶⁶ Show member pathways Chk1/Chk2(Cds1) mediated inactivation of Cyclin B-Cdk1 complex ⁶⁶ DNA damage_DNA-damage-induced responses ²² DNA Repair ⁶⁶ G2/M DNA damage checkpoint ⁶⁶ HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA) ⁶⁶ HDR through MMEJ (alt-NHEJ) ⁶⁶ Homology Directed Repair ⁶⁶ Non-homologous end joining ¹ Non-homologous end-joining ³⁷ Processing of DNA double-strand break ends ⁶⁶	13.37	ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
4	Regulation of TP53 Activity ⁶⁶ Show member pathways Regulation of TP53 Activity through Association with Co-factors ⁶⁶ Regulation of TP53 Activity through Methylation ⁶⁶ Regulation of TP53 Activity through Phosphorylation ⁶⁶ Transcriptional Regulation by TP53 ⁶⁶	13.11	ATM BARD1 BRCA1 BRIP1 CHEK2 MLH1
5	TCR Signaling (Qiagen) ⁶⁴ Show member pathways Fc-EpsilonRI Pathway ⁶⁴ PDGF Pathway ⁶⁴ PKC-Theta Pathway ⁶⁴ TCR Signaling ⁶⁴	13.05	ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
6	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.88	BRCA2 MLH1 MSH2 PTEN RAD51 TP53
7	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ Parkinson's Disease Pathway ⁶⁴ SREBP Proteolysis ⁶⁴	12.86	ATM BARD1 BRCA1 BRCA2 CHEK2 MRE11
8	Pathways in cancer ³⁷	12.85	BRCA2 MLH1 MSH2 PTEN RAD51 TP53
9	Cell Cycle Checkpoints ⁶⁶ Show member pathways G2/M Checkpoints ⁶⁶	12.8	ATM BARD1 BRCA1 BRIP1 CHEK2 MRE11
10	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.75	ATM BRCA1 BRCA2 PTEN TP53
11	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.75	BRCA1 BRCA2 MLH1 PTEN TP53
12	Meiosis ⁶⁶ Show member pathways Meiotic recombination ⁶⁶ Meiotic synapsis ⁶⁶	12.65	ATM BRCA1 BRCA2 MLH1 MRE11 NBN
13	DNA Damage ⁴	12.57	ATM BRCA1 BRCA2 BRIP1 CHEK2 MLH1
14	DNA Double Strand Break Response ⁶⁶ Show member pathways Nonhomologous End-Joining (NHEJ) ⁶⁶ Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks ⁶⁶ Sensing of DNA Double Strand Breaks ⁶⁶	12.55	ATM BARD1 BRCA1 CHEK2 MRE11 NBN
15	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁷	12.55	ATM BRCA1 CHEK2 MRE11 NBN PTEN
16	Homologous DNA Pairing and Strand Exchange ⁶⁶ Show member pathways ATR Signaling ¹ HDR through Homologous Recombination (HRR) ⁶⁶ HDR through Single Strand Annealing (SSA) ⁶⁶ Presynaptic phase of homologous DNA pairing and strand exchange ⁶⁶	12.52	ATM BARD1 BRCA1 BRCA2 BRIP1 MRE11
17	MicroRNAs in cancer ³⁷	12.47	ATM BRCA1 PTEN TP53
18	DNA Damage/Telomere Stress Induced Senescence ⁶⁶ Show member pathways Formation of Senescence-Associated Heterochromatin Foci (SAHF) ⁶⁶ Packaging Of Telomere Ends ⁶⁶ Signal transduction Activin A signaling regulation ²²	12.39	ATM MRE11 NBN RAD50 TP53
19	Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) ⁶⁶ Show member pathways Homologous recombination ³⁷ Homologous recombination ¹ Resolution of D-Loop Structures ⁶⁶ Resolution of D-loop Structures through Holliday Junction Intermediates ⁶⁶	12.36	ATM BARD1 BRCA1 BRCA2 BRIP1 MRE11
20	Cellular senescence (KEGG) ³⁷	12.34	ATM CHEK2 MRE11 NBN PTEN RAD50
21	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.31	ATM BRCA1 CHEK2 PTEN TP53
22	Direct p53 effectors ¹	12.08	MLH1 MSH2 PTEN TP53
23	Integrated Breast Cancer Pathway ¹	12.08	ATM BARD1 BRCA1 BRCA2 CHEK2 MRE11
24	Fanconi anemia pathway ⁶⁶ ³⁷	12.06	BRCA1 BRCA2 BRIP1 MLH1 PALB2 RAD51
25	ATM Pathway ⁶⁴ Show member pathways ATM Signaling Pathway ¹	12.04	ATM BRCA1 CHEK2 MRE11 NBN RAD50
26	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.92	ATM BARD1 BRCA1 BRCA2 CHEK2 MRE11
27	Platinum drug resistance ³⁷	11.88	ATM BRCA1 MLH1 MSH2 TP53
28	Mismatch repair ³⁷ ⁶⁶ ¹ Show member pathways Mismatch repair (MMR) directed by MSH2-MSH3 (MutSbeta) ⁶⁶ Mismatch repair (MMR) directed by MSH2-MSH6 (MutSalpha) ⁶⁶ Mismatch Repair in Eukaryotes ⁶⁴	11.86	MLH1 MSH2 PMS1
29	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.83	ATM BRCA1 CHEK2 PTEN TP53
30	Regulation of Telomerase ¹	11.75	ATM MRE11 NBN RAD50
31	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.72	ATM CHEK2 TP53
32	DNA damage_ATM/ATR regulation of G1/S checkpoint ²²	11.68	ATM BARD1 BRCA1 CHEK2 NBN TP53
33	ATM Signaling Network in Development and Disease ¹	11.66	ATM CHEK2 MRE11 NBN RAD50
34	p53 pathway ¹	11.63	ATM CHEK2 TP53
35	Cell cycle Role of 14-3-3 proteins in cell cycle regulation ²² Show member pathways 14-3-3 and Cell Cycle Regulation ⁶⁴	11.5	ATM CHEK2 TP53
36	Busulfan Pathway, Pharmacodynamics ⁶¹ Show member pathways Catalytic cycle of mammalian Flavin-containing MonoOxygenases (FMOs) ¹ FMO oxidises nucleophiles ⁶⁶	11.49	CHEK2 MLH1 MSH2
37	Doxorubicin Pathway, Pharmacokinetics ⁶¹ Show member pathways Doxorubicin Pathway (Cancer Cell), Pharmacodynamics ⁶¹	11.44	MLH1 MSH2 TP53
38	GADD45 Pathway ⁶⁴	11.33	ATM BRCA1 TP53
39	DNA damage_NHEJ mechanisms of DSBs repair ²²	11.3	BRCA1 MRE11 NBN RAD50
40	Integrated Cancer Pathway ¹	11.27	ATM BARD1 BRCA1 CHEK2 MRE11 MSH2
41	DDX1 as a regulatory component of the Drosha microprocessor ¹ Show member pathways RNA interference ¹	11.11	ATM MRE11 NBN RAD50
42	DNA Damage Induced 14-3-3Sigma Signaling ⁶⁴	11.1	ATM BRCA1 TP53
43	BARD1 signaling events ¹	10.69	ATM BARD1 BRCA1 MRE11 NBN RAD50
44	PLK3 signaling events ¹	10.37	CHEK2 TP53

Sources

GO Terms for Hereditary Breast Ovarian Cancer Syndrome

Cellular components related to Hereditary Breast Ovarian Cancer Syndrome according to GeneCards Suite gene sharing:

(show all 17)

#	Name	GO ID	Score	Top Affiliating Genes
1	PML body	GO:0016605	9.88	CHEK2 MRE11 NBN PTEN RAD51 TP53
2	condensed nuclear chromosome	GO:0000794	9.76	BRCA1 MLH1 RAD50 RAD51
3	nuclear chromosome, telomeric region	GO:0000784	9.76	ATM BRCA2 MRE11 MSH2 NBN RAD50
4	site of double-strand break	GO:0035861	9.73	MRE11 NBN RAD50 RAD51
5	chromosome, telomeric region	GO:0000781	9.73	ATM CHEK2 MRE11 NBN RAD50 RAD51D
6	condensed chromosome	GO:0000793	9.72	BRCA1 MLH1 RAD51
7	lateral element	GO:0000800	9.69	BRCA1 BRCA2 RAD51
8	mismatch repair complex	GO:0032300	9.67	MLH1 MSH2 PMS1
9	Mre11 complex	GO:0030870	9.65	MRE11 NBN RAD50
10	Rad51B-Rad51C-Rad51D-XRCC2 complex	GO:0033063	9.62	RAD51 RAD51C RAD51D XRCC2
11	nucleoplasm	GO:0005654	9.58	ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
12	MutLalpha complex	GO:0032389	9.57	MLH1 PMS1
13	BRCA1-A complex	GO:0070531	9.56	BARD1 BRCA1
14	BRCA1-BARD1 complex	GO:0031436	9.54	BARD1 BRCA1
15	replication fork	GO:0005657	9.43	NBN RAD51 RAD51C RAD51D TP53 XRCC2
16	nucleus	GO:0005634	10.35	ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
17	chromosome	GO:0005694	10	BRCA1 MLH1 MRE11 NBN RAD50 RAD51D

Biological processes related to Hereditary Breast Ovarian Cancer Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 66)

#	Name	GO ID	Score	Top Affiliating Genes
1	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.99	ATM BRCA1 BRCA2 CHEK2 MLH1 MSH2
2	telomere maintenance	GO:0000723	9.98	ATM MRE11 NBN RAD50 RAD51D
3	strand displacement	GO:0000732	9.97	ATM BARD1 BRCA1 BRCA2 BRIP1 MRE11
4	DNA duplex unwinding	GO:0032508	9.96	BRIP1 MRE11 NBN RAD50
5	DNA double-strand break processing	GO:0000729	9.95	ATM BARD1 BRCA1 MRE11 NBN RAD50
6	response to gamma radiation	GO:0010332	9.93	BRCA2 CHEK2 TP53 XRCC2
7	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	GO:0042771	9.92	BRCA2 CHEK2 MSH2 TP53
8	response to X-ray	GO:0010165	9.91	BRCA2 MSH2 TP53 XRCC2
9	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	9.91	BRCA1 BRCA2 CHEK2 TP53
10	multicellular organism growth	GO:0035264	9.9	ATM PALB2 XRCC2
11	positive regulation of kinase activity	GO:0033674	9.9	MRE11 NBN RAD50
12	mitotic recombination	GO:0006312	9.9	RAD51 RAD51C RAD51D XRCC2
13	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	9.89	ATM CHEK2 TP53
14	somitogenesis	GO:0001756	9.88	ATM PALB2 XRCC2
15	telomere maintenance via recombination	GO:0000722	9.88	BRCA2 RAD50 RAD51 RAD51C
16	nucleotide-excision repair	GO:0006289	9.87	BRCA2 RAD51D TP53
17	mismatch repair	GO:0006298	9.87	MLH1 MSH2 PMS1
18	DNA damage checkpoint	GO:0000077	9.87	BRIP1 CHEK2 NBN
19	DNA recombinase assembly	GO:0000730	9.87	RAD51 RAD51C RAD51D XRCC2
20	synapsis	GO:0007129	9.86	BRIP1 MLH1 MRE11
21	chromosome organization	GO:0051276	9.86	BRCA2 MRE11 RAD51D
22	cellular response to gamma radiation	GO:0071480	9.86	ATM CHEK2 TP53
23	positive regulation of protein autophosphorylation	GO:0031954	9.85	MRE11 NBN RAD50
24	strand invasion	GO:0042148	9.85	RAD51 RAD51C RAD51D XRCC2
25	isotype switching	GO:0045190	9.84	MLH1 MSH2 NBN
26	replicative senescence	GO:0090399	9.84	ATM CHEK2 TP53
27	meiotic DNA recombinase assembly	GO:0000707	9.84	RAD51 RAD51C RAD51D XRCC2
28	determination of adult lifespan	GO:0008340	9.83	ATM MSH2 TP53
29	positive regulation of telomere maintenance	GO:0032206	9.82	MRE11 NBN RAD50
30	chromosome organization involved in meiotic cell cycle	GO:0070192	9.82	ATM RAD50 RAD51
31	negative regulation of telomere capping	GO:1904354	9.8	ATM NBN RAD50
32	telomeric 3 overhang formation	GO:0031860	9.79	MRE11 NBN RAD50
33	somatic hypermutation of immunoglobulin genes	GO:0016446	9.74	MLH1 MSH2
34	intra-S DNA damage checkpoint	GO:0031573	9.73	MRE11 MSH2
35	DNA damage response, signal transduction by p53 class mediator	GO:0030330	9.73	NBN TP53
36	postreplication repair	GO:0006301	9.73	BRCA1 MSH2
37	inner cell mass cell proliferation	GO:0001833	9.73	BRCA2 PALB2
38	signal transduction in response to DNA damage	GO:0042770	9.72	CHEK2 NBN
39	positive regulation of isotype switching to IgG isotypes	GO:0048304	9.72	MLH1 MSH2
40	meiotic telomere clustering	GO:0045141	9.72	ATM MLH1
41	protein K6-linked ubiquitination	GO:0085020	9.72	BARD1 BRCA1
42	DNA damage induced protein phosphorylation	GO:0006975	9.71	ATM CHEK2
43	positive regulation of isotype switching to IgA isotypes	GO:0048298	9.7	MLH1 MSH2
44	somatic recombination of immunoglobulin gene segments	GO:0016447	9.7	MLH1 MSH2
45	chordate embryonic development	GO:0043009	9.7	BRCA1 BRCA2
46	double-strand break repair via homologous recombination	GO:0000724	9.7	ATM BRCA1 BRCA2 MRE11 NBN PALB2
47	mitotic recombination-dependent replication fork processing	GO:1990426	9.68	BRCA2 RAD51
48	somatic recombination of immunoglobulin genes involved in immune response	GO:0002204	9.68	MLH1 MSH2
49	regulation of mitotic recombination	GO:0000019	9.67	MRE11 RAD50
50	reciprocal meiotic recombination	GO:0007131	9.23	ATM MLH1 MRE11 RAD50 RAD51 RAD51C

Molecular functions related to Hereditary Breast Ovarian Cancer Syndrome according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	double-stranded DNA binding	GO:0003690	9.91	MRE11 MSH2 RAD51 RAD51C RAD51D XRCC2
2	ATPase activity	GO:0016887	9.87	MLH1 MSH2 PMS1 RAD50
3	protein C-terminus binding	GO:0008022	9.85	BRCA2 MRE11 MSH2 RAD51
4	damaged DNA binding	GO:0003684	9.81	BRCA1 MSH2 NBN TP53
5	DNA-dependent ATPase activity	GO:0008094	9.8	MSH2 RAD51 RAD51C RAD51D XRCC2
6	ATP-dependent DNA helicase activity	GO:0004003	9.76	BRIP1 MRE11 NBN RAD50
7	protein N-terminus binding	GO:0047485	9.75	ATM NBN TP53
8	mismatched DNA binding	GO:0030983	9.67	MLH1 MSH2 PMS1
9	single-stranded DNA endodeoxyribonuclease activity	GO:0000014	9.56	MRE11 RAD50
10	recombinase activity	GO:0000150	9.56	RAD51 RAD51C RAD51D XRCC2
11	endodeoxyribonuclease activity	GO:0004520	9.55	MRE11 RAD51 RAD51C RAD51D XRCC2
12	guanine/thymine mispair binding	GO:0032137	9.52	MLH1 MSH2
13	four-way junction DNA binding	GO:0000400	9.35	MSH2 RAD51 RAD51C RAD51D XRCC2
14	single-stranded DNA binding	GO:0003697	9.23	BRCA2 MLH1 MSH2 PMS1 RAD51 RAD51C
15	protein binding	GO:0005515	10.49	ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
16	DNA binding	GO:0003677	10.17	ATM BRCA1 BRCA2 BRIP1 MRE11 MSH2
17	ATP binding	GO:0005524	10.15	ATM BRIP1 CHEK2 MLH1 MSH2 PMS1
18	nucleotide binding	GO:0000166	10.02	ATM BRIP1 CHEK2 RAD50 RAD51 RAD51C

Sources

Sources for Hereditary Breast Ovarian Cancer Syndrome

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia